Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon
April 29 (Reuters) - Orchestra Biomed Holdings Inc OBIO.O:
ORCHESTRA BIOMED RECEIVES FDA APPROVAL OF IDE TO INITIATE U.S. CORONARY PIVOTAL TRIAL RANDOMIZING FIRST-IN-CLASS SIROLIMUS-ANGIOINFUSION BALLOON, VIRTUE SAB, HEAD-TO-HEAD WITH PACLITAXEL-COATED BALLOON
ORCHESTRA BIOMED HOLDINGS INC: TARGETING INITIATION OF VIRTUE TRIAL DURING SECOND HALF OF 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.